- Series 2017A revenue bonds
- Series 2017B revenue bonds
- Series 2017C revenue bonds
- Series 2015A revenue bonds
- Series 2011A revenue bonds
- Series 2009A revenue bonds
The outlook is positive, reflecting the cancer center’s strengthening balance sheet in fiscal year 2016 and the subsequent liquidation of a portion of its stock in Seattle-based Juno Therapeutics, which bolstered the cancer center’s cash and investments during the past two fiscal years.
More articles on healthcare finance:
S&P places MetroHealth System’s ‘A-‘ bonds on CreditWatch
S&P lowers North Oaks Health System’s rating to ‘BB+’ on select bonds
Fitch assigns ‘AA-‘ rating to University Medical Center of El Paso’s bonds
